The NIHGPS provides both up-to-date policy guidance that serves as NIH standard terms and conditions of awards for grants and cooperative agreements, and extensive guidance to individuals that are interested in pursuing NIH grants.
The revision incorporates NIH policy changes since the December 2003 version, policy clarifications, public policy changes, terminology changes, new chapters, chapter revisions, reorganization of the document, as well as other document enhancements such as a new chapter numbering schema. Some sections have been rewritten to provide clarity; however, the overall policies have not changed. The revised policy is available at http://grants.nih.gov/grants/policy/nihgps_2010/index.htm. Significant changes also are outlined in the following document: http://grants.nih.gov/grants/policy/nihgps_2010/Significant_Changes_NIH_GPS_10_1_2010.doc.  

The University of Miami, Nature Publishing Group and Scripps Florida invite you to attend "Epigenetics in Development and Disease," the 44th Miami Winter Symposium, February 6 through 9 at the JW Marriott Marquis Miami, 345 Avenue of the Americas. University of Miami faculty, staff and students may apply for sponsorship, which if accepted, would cover the cost of registration. A limited number of sponsorships are available and will be handled on a first-come, first-served basis.

This year's symposium will feature awardees and guest speakers Peter Jones, Ph.D., D.Sc., The H. Leslie Hoffman and Elaine S. Hoffman Chair in Cancer Research  at the University of Southern California; Andrew Feinberg, M.D., M.P.H., King Fahd Professor of Molecular Medicine at Johns Hopkins School of Medicine; Rudolf Jaenisch, M.D., professor of biology at  Massachusetts Institute of Technology; and Danesh Moazed, Ph.D., professor of cell biology at Harvard Medical School.

Sponsorship applications are due November 19, and priority will be given to post-doctoral and graduate students and to those presenting a poster. Early bird rates are available for all other applications received by November 18. For more information or to download an application, please visit the symposium website.

The methods, which include "a targeted/opsonized nanoparticle based platform," "in vivo electroporation," and "Water-In-Oil liposome based platform," have notable advantages. For one, they eliminate the need for "protein purification." For another, plasmids for encoding any protein/antigen are easy to obtain, produce or purchase, and result in the expression of native forms of the antigen/proteins.

Other services available at the BMC include the design of immunogenic fusion peptides and standard methods for generation of monoclonal antibodies.

For further information or to arrange use of such services, please contact Pirouz Daftarian Ph.D., director of the Biological Modifiers Laboratory, at 305-243-7919 or pdaftarian@med.miami.edu.

Notification of the CRIS office or the Jackson Health System Clinical Trials Office (JHS-CTO) of subject enrollment at UM or JHS does not relieve investigators of their responsibility to notify the Institutional Review Board (IRB) of subject enrollment at the time of the protocol's continuing report submission per IRB policy. If subjects are enrolled at or participate in studies at a JHS facility, investigators are also responsible for notifying the JHS-CTO within 24 hours, as required per JHS policy.

More information:

• CRIS subject enrollment policy

• Velos login

• FAQs on the CRIS subject enrollment policy

• IRB policy

• JHS policy

• Effective April 1, the JHS CTO will require principal investigators or their designated research staff to complete a research encounter ticket for each patient's protocol-related visit. The new form will enable the JHS CTO to accurately bill and designate the correct modifiers for routine care and study-related care on claims, as required by the Centers for Medicare and Medicaid Services. The research encounter ticket will be required in addition to the patient consent form. For more information, please contact Eve Sakran at ESakran@jhsmiami.org.
 
• JHS CTO has revised its application form (available at http://uresearch.miami.edu/?p=268). Fees have changed and waivers will need to be requested on a case-by-case basis. Please send your materials to CRIS at cris@med.miami.edu for review before sending them to the JHS CTO.
• CRIS has revised their forms for new studies and amendments to make them more user-friendly (available at http://uresearch.miami.edu/?p=268). For more information, please send an e-mail to cris@med.miami.edu.  

• Research Listserv: Read about funding opportunities and updates to policies and procedures from external funding agencies and the University. You may also post questions, and find collaborators and specialized resources.

• Research Administrators Listserv: Read about funding opportunities and updates to policies and procedures from external funding agencies and the University. You may also post questions and connect with other research administrators.

• Clinical Research Listserv: This listserv is designed for human subjects researchers to learn about new policies, training and education opportunities, and process changes from the University. Share information on clinical research and find collaborators and specialized resources.

• International Research Listserv: Join this listserv for faculty, staff and students engaged in international research. Post questions and share information on topics of interest.

Visit uresearch.miami.edu to subscribe.

Interested in a Recovery Act Opportunity?
If you are interested in a Recovery Act opportunity, please submit your proposal(s) to Jill Tincher at jtincher@med.miami.edu at least five business days prior to the submission deadline. Remember to review the request for applications carefully for specific budget and reporting requirements.

For more information, visit the stimulus funding Web site at www.miami.edu/research/recovery or subscribe to the research listservs at http://uresearch.miami.edu/.